Literature DB >> 16626421

Pars plana insertion of glaucoma drainage devices for refractory glaucoma.

M Hannah Pu de Guzman1, Alejandro Valencia, Adrian C Farinelli.   

Abstract

BACKGROUND: Glaucoma drainage devices are more commonly inserted into the anterior chamber because of the relative ease of this method of insertion. However, in certain cases, posterior placement of the tube may be necessary or may be more desirable. The outcome of a series of patients with glaucoma drainage devices inserted into the pars plana was examined.
METHODS: Retrospective chart review of patients who underwent pars plana implantation of Molteno and Baerveldt glaucoma drainage devices at the Sydney Eye Hospital.
RESULTS: There were 33 cases reviewed. The mean follow-up period was 30.2 months. The mean final postoperative intraocular pressure was reduced to 13.4 +/- 4.4 mmHg (SD) from 33.06 +/- 8.47 mmHg preoperatively. The mean number of intraocular pressure-lowering medications in use postoperatively was 0.6 +/- 0.8, reduced from 3.6 +/- 1.27 medications in use preoperatively. Sixteen (48.5%) eyes were classified as complete successes, 14 (42.4%) eyes as qualified successes and three eyes (9%) as failures. Kaplan-Meier survival analysis for cumulative success (absence of failure) predicted 61.1% survival at 60 months. Complications included five cases of decompensation of corneas or corneal grafts, one case each of conjunctival wound dehiscence, large choroidal effusion, epiretinal membrane, Molteno plate extrusion and intraocular pressure unresponsive to medical therapy, and three cases of tube blockage.
CONCLUSIONS: In this series of patients, pars plana insertion of glaucoma drainage devices has been shown to be an effective alternative for selected cases where anterior chamber tube insertion is not possible or is not ideal.

Entities:  

Mesh:

Year:  2006        PMID: 16626421     DOI: 10.1111/j.1442-9071.2006.01170.x

Source DB:  PubMed          Journal:  Clin Exp Ophthalmol        ISSN: 1442-6404            Impact factor:   4.207


  7 in total

1.  Long-term results of combined endoscope-assisted pars plana vitrectomy and glaucoma tube shunt surgery.

Authors:  Ryan M Tarantola; Anita Agarwal; Pengcheng Lu; Karen M Joos
Journal:  Retina       Date:  2011-02       Impact factor: 4.256

2.  Pars plana Baerveldt tube insertion with pars plana vitrectomy for refractory glaucoma.

Authors:  Anton M Kolomeyer; H Jane Kim; Albert S Khouri; Paul J Lama; Robert D Fechtner; Marco A Zarbin; Neelakshi Bhagat
Journal:  Oman J Ophthalmol       Date:  2012-01

3.  Clinical outcome of a nonvalved Aurolab aqueous drainage implant in posterior segment versus anterior chamber.

Authors:  Devendra Maheshwari; Shylesh Dabke; Sindhushree Rajagopal; Mohideen A Kadar; Rengappa Ramakrishnan
Journal:  Indian J Ophthalmol       Date:  2019-08       Impact factor: 1.848

4.  Combined pars plana glaucoma drainage device placement and vitrectomy using a vitrectomy sclerotomy site for tube placement: a case series.

Authors:  Enchi Kristina Chang; Sanchay Gupta; Marika Chachanidze; John B Miller; Ta Chen Chang; David A Solá-Del Valle
Journal:  BMC Ophthalmol       Date:  2021-02-25       Impact factor: 2.209

5.  Long-term Outcomes of Ahmed Glaucoma Valve Implantation in Refractory Glaucoma at Farabi Eye Hospital, Tehran, Iran.

Authors:  Reza Zarei; Heidar Amini; Ramin Daneshvar; Fahimeh Naderi Nabi; Sasan Moghimi; Ghasem Fakhraee; Yadollah Eslami; Masoud Mohammadi; Nima Amini
Journal:  Middle East Afr J Ophthalmol       Date:  2016 Jan-Mar

6.  Vitrectomy combined with posterior-segment Ahmed valve implant: A case series study.

Authors:  M de Frutos-Lezaun; I Rodriguez-Agirretxe; F Eder Labairu; C Irigoyen
Journal:  Saudi J Ophthalmol       Date:  2018-03-15

7.  Surgical management of raised intra-ocular tension in the hostile ocular surface - recurrent tube erosion in a patient with systemic sclerosis: a case report.

Authors:  Gurjeet Jutley; Elizabeth Yang; Phillip Bloom
Journal:  BMC Ophthalmol       Date:  2018-09-14       Impact factor: 2.209

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.